^
    5d
    Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. (PubMed, Adv Sci (Weinh))
    Here, we use photoactivatable multi-inhibitor liposomes (PMILs) as a clinically translatable strategy to immunomodulate and enhance PDAC treatment using FDA-approved agents: minocycline for tumor priming by downregulating Tdp1, benzoporphyrin derivative incorporated into the liposomal bilayer for photodynamic priming (PDP) of the microenvironment, and irinotecan (IRI) for cytotoxicity. This combination achieved sustained local tumor regression, abscopal effects in untreated distant tumors, and a significant improvement in long-term survival (63%). By integrating clinically approved agents with non-overlapping mechanisms within a light-activated delivery platform, this approach enhances IRI efficacy, reprograms the TME, and promotes antitumor immunity, offering a translatable strategy to sensitize PDAC to chemo- and immunotherapy.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    irinotecan • minocycline
    6d
    XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process. (PubMed, Oncogene)
    Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS.
    Journal
    |
    XPO1 (Exportin 1)
    |
    everolimus • Xpovio (selinexor) • Synribo (omacetaxine mepesuccinate)
    7d
    Preventive antibiotic treatment during childbirth for the prevention of Group G and C Streptococcal infections (2024-519263-18-00)
    P4, N=696, Recruiting, University Of Oulu | Not yet recruiting --> Recruiting
    Enrollment open
    7d
    Intravesical Gentamicin to Prevent Recurrent UTI (clinicaltrials.gov)
    P4, N=20, Completed, Women and Infants Hospital of Rhode Island | Recruiting --> Completed | N=30 --> 20
    Trial completion • Enrollment change
    8d
    EMPHASIS-2: Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (clinicaltrials.gov)
    P3, N=934, Not yet recruiting, Beijing Tiantan Hospital
    New P3 trial
    |
    minocycline
    9d
    Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo (clinicaltrials.gov)
    P4, N=100, Not yet recruiting, Bausch Health Americas, Inc.
    New P4 trial
    14d
    Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study (clinicaltrials.gov)
    P1, N=94, Not yet recruiting, Zhongda Hospital
    New P1 trial
    |
    docetaxel • Nubeqa (darolutamide) • goserelin acetate • Synribo (omacetaxine mepesuccinate)
    14d
    HVA-MPAL: HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). (clinicaltrials.gov)
    P2, N=40, Enrolling by invitation, Guangdong Second Provincial General Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    15d
    Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma. (PubMed, Int J Biol Sci)
    Furthermore, combined pharmacological inhibition of FOXM1 (FDI-6, RCM-1, thiostrepton) and BUB1 (BAY-1816032) synergistically inhibited the proliferation of HCC cells and xenograft tumors. These findings establish FOXM1-mediated BUB1 upregulation as a key driver of HCC malignancy. Targeting the FOXM1/BUB1 axis represents a promising therapeutic strategy for the treatment of advanced and metastatic HCC, offering new opportunities for HCC therapy.
    Journal
    |
    FOXM1 (Forkhead Box M1) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase)
    |
    BAY-1816032 • thiostrepton (RSO-021)
    15d
    Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial. (PubMed, Nat Commun)
    PLD1-inhibitor remodeled phospholipid metabolism, induced ferroptosis and restored QUIZOM response in LSC. Our findings provided the therapeutic and resistant mechanisms of QUIZOM and paved the way for targeted interventions in this AML subtype.
    P2 data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)
    |
    NPM1 mutation
    |
    Vanflyta (quizartinib) • Synribo (omacetaxine mepesuccinate)
    15d
    Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=26, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2027 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • cyclophosphamide • Blincyto (blinatumomab) • vincristine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
    15d
    Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections (clinicaltrials.gov)
    P1, N=104, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting
    Enrollment open